The effect of a multidisciplinary program on HAART adherence

被引:25
作者
Frick, Pamela
Tapia, Kenneth
Grant, Philip
Novotny, Martina
Kerzee, Jane
机构
[1] Sch Pharm, Seattle, WA USA
[2] Univ Washington, AIDS Res Ctr, Biostat Core, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Seattle, WA 98195 USA
[4] Kaiser Permanente, Denver, CO USA
关键词
D O I
10.1089/apc.2006.20.511
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Although emerging evidence suggests differing interventions may improve antiretroviral adherence, there has not been a formal evaluation to identify the impact of a clinic-based multidisciplinary program designed to provide education and identify and correct potential adherence barriers prior to the initiation of highly active antiretroviral therapy ( HAART). A retrospective cohort study utilizing a historical control group was conducted to compare duration on antiretrovirals, clinical indicators, and adherence rates, as captured by pharmacy refill records. Two hundred sixty-one patients met criteria for inclusion (109 subjects, 152 controls). Time to stopping antiretrovirals, as evidenced by Kaplan-Meier plot, was significantly higher in Protocol group than Controls (log-rank p = 0.023): the median duration on HAART for the intervention group was greater than 360 days but only 210 days for the control group. Thus, more subjects in the protocol group continued on therapy for the full year: 60 (55%) versus 65 (43%) for the control group. The mean reduction in log(10) viral loads between HAART initiation and 12 months was greatest for the intervention group with viral load at HAART initiation 100,000 copies per milliliter or more, -3.57 versus -1.78 for controls with viral load less than 100,000 copies per milliliter (p < 0.001). For the intervention group, the mean number of adherence barriers identified per person was 4% and 72% were found to have three or more barriers. Patients at high risk for poor adherence benefit from multidisciplinary education and proactive identification of adherence barriers by exhibiting prolonged duration on therapy and greater reduction in log(10) viral loads.
引用
收藏
页码:511 / 524
页数:14
相关论文
共 28 条
[1]   HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial:: an extended virology study [J].
Aboulker, JP ;
Babiker, AG ;
Brun-Vézinet, F ;
Darbyshire, JH ;
Flandre, P ;
Gazzard, B ;
Nunn, AJ ;
Goodall, R ;
Aber, V ;
Bragman, K ;
Breckenridge, AM ;
Carbon, C ;
Charreau, I ;
Chene, G ;
Collis, P ;
Cooper, D ;
Dormont, J ;
Fiddian, P ;
Flepp, M ;
Goebel, FD ;
Hooker, M ;
Lange, J ;
Lüthy, R ;
Peto, TEA ;
Reiss, P ;
Seligmann, M ;
Stone, AB ;
Thomis, J ;
Vella, S ;
Walckenaer, G ;
Warrell, D ;
Weller, IVD ;
Wilber, R ;
Yeni, P ;
Yeo, J ;
Withnall, R ;
Goudsmit, J ;
Huraux, JM ;
van der Noorda, J ;
Weiss, R ;
Boucher, C ;
Schuurman, R ;
Descamps, D ;
Jeffries, D ;
Tedder, R ;
Weber, J ;
Krzyanowski, C ;
Weverling, G .
AIDS, 1999, 13 (01) :57-65
[2]   Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature [J].
Ammassari, A ;
Trotta, MP ;
Murri, R ;
Castelli, F ;
Narciso, P ;
Noto, P ;
Vecchiet, J ;
D'Arminio Monforte, A ;
Wu, AW ;
Antinori, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S123-S127
[3]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[4]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[5]  
CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9
[6]   Impact of an alarm device on medication compliance in women in Mombasa, Kenya [J].
Frick, PA ;
Lavreys, L ;
Mandaliya, K ;
Kreiss, JK .
INTERNATIONAL JOURNAL OF STD & AIDS, 2001, 12 (05) :329-333
[7]   Adherence and potency with antiretroviral therapy: A combination for success [J].
Gathe, J .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 :S118-S122
[8]   Pharmaceutical services in an HIV clinic [J].
Geletko, SM ;
Poulakos, MN .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (08) :709-713
[9]   Impact of a patient education program on adherence to HIV medication -: A randomized clinical trial [J].
Goujard, C ;
Bernard, N ;
Sohier, N ;
Peyramond, D ;
Lançon, F ;
Chwalow, J ;
Arnould, B ;
Delfraissy, JF .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (02) :191-194
[10]   The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response [J].
Haubrich, RH ;
Little, SJ ;
Currier, JS ;
Forthal, DN ;
Kemper, CA ;
Beall, GN ;
Johnson, D ;
Dubé, MP ;
Hwang, JY ;
McCutchan, JA .
AIDS, 1999, 13 (09) :1099-1107